Pricing Log in Create free account

Biofrontera Inc. (BFRI) vs InMed Pharmaceuticals Inc. (INM)

Biofrontera Inc. and InMed Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Biofrontera Inc. is the larger, with a market value of $12.0M against $7.3M — 1.7× the size. Biofrontera Inc. grew revenue faster over the last twelve months: 17.8% against −6.73%. InMed Pharmaceuticals Inc. has the higher net margin (0.00% vs −13.8%) and the higher return on invested capital (0.00% vs −69.5%). Across the 16 metrics below, Biofrontera Inc. leads on 8 and InMed Pharmaceuticals Inc. on 8.

Valuation

Metric BFRI INM Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S 0.23 15.78 2.08
P/B 1.78 n/m 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA n/m n/m 12.22
EV/Sales 0.23 15.54 2.87
Earnings yield (72.84%) (23.08%) (15.94%)
Free cash flow yield (74.83%) (11.11%) 0.00%

Profitability

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Gross margin 79.25% 33.62% 53.51%
Operating margin (14.22%) 0.00% 0.00%
Net margin (13.78%) 0.00% (2.45%)
Free cash flow margin (17.17%) 0.00% 0.00%
Return on equity (988.35%) (261.69%) (0.80%)
Return on assets (28.80%) (185.40%) (1.67%)
Return on invested capital (69.45%) 0.00% 0.00%

Growth

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 17.83% (6.73%) 5.22%
EPS growth (last fiscal year) 67.70% 62.68% 42.91%
Revenue growth, 5-year CAGR 17.21% — 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Debt to equity 0.78 0.00 0.04
Current ratio 1.18 0.50 2.41
Net debt to EBITDA 0.17 0.20 1.01

Dividend

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Market cap 11.99m 7.26m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack